COVID-19 Seroprevalence in Pregnant Women and Blood Donors

NCT ID: NCT04893057

Last Updated: 2024-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

797 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-15

Study Completion Date

2023-01-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these measures are representative of the general population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Respiratory Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women

Women admitted to hospital for a live birth.

No interventions assigned to this group

Blood donors

Subjects qualified for whole blood donation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women

* Adult female
* Admitted to hospital for live birth
* Informed consent
* Affiliated to the French social security health insurance scheme
* Blood donors

* Adult male or female
* Qualified for whole blood donation (up to 70 years old in France)
* Informed consent
* Affiliated to the French social security health insurance scheme

Exclusion Criteria

* Legal incapacity or limited legal capacity
* Subject without health insurance coverage
* Exclusion period of another study or exclusion period of the French national healthy volunteer registry
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maxime Desmarets, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

CHU Besançon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de besançon

Besançon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/601

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ANC COVID-19 Surveillance
NCT07021807 COMPLETED